第 2 阶段试验的反应率达到 100%，表明 dostarlimab 可有效治疗错配修复缺陷型直肠癌。 100% response rate in phase 2 trial indicates dostarlimab effectively treats mismatch repair deficient rectal cancer.

第 2 阶段试验的反应率达到 100%，表明 dostarlimab (Jemperli) 可有效治疗局部晚期错配修复缺陷直肠癌。 100% response rate in a phase 2 trial suggests dostarlimab (Jemperli) effectively treats locally advanced mismatch repair deficient rectal cancer. 该药物是一种 PD-1 阻断抗体，为手术和化疗提供了一种有希望的替代方案。 The drug, which is a PD-1-blocking antibody, offers a promising alternative to surgery and chemotherapy. 试验中所有 42 名患者均表现出临床完全反应，扫描未检测到肿瘤。 All 42 patients in the trial showed clinical complete responses, with no tumours detected on scans.